AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34213870
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate (40mg) and lidocaine (40mg in 20 mL)
Trial: 32109160
Drug: High-dose SVF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose SVF
Trial: 32109160
Drug: Low-dose SVF
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose SVF
Trial: 34845913
Drug: Single-species mite
RxNorm normalized name: mite extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-species mite allergen immunotherapy
Trial: 34845913
Drug: Double-species mite
RxNorm normalized name: mite extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-species mite allergen immunotherapy
Trial: 34480096
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (anthracycline or taxane)
Trial: 32270631
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical acupoint stimulation (TEAS) combined with conventional western medicine
Trial: 33754604
Drug: Intracorporeal injection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracorporeal injection (ICI)
Trial: 33754604
Drug: Intracorporeal injection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracorporeal injection (ICI) + phosphodiesterase inhibitor (PDE5i)
Trial: 33754604
Drug: Phosphodiesterase inhibitor
RxNorm normalized name: Phosphodiesterase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphodiesterase inhibitor (PDE5i)
Trial: 35220651
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MELD and CYFRA21‐1
Trial: 32243651
Drug: 5 ng/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ng/mL recombinant basic fibroblast growth factor (bFGF) and 25 mg/500 mL 3′5′ cyclic adenosine monophosphate (cAMP) (Group B)
Trial: 32621663
Drug: Topical triamcinolone
RxNorm normalized name: triamcinolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical triamcinolone acetonide 0.1% ointment twice daily for 2 weeks
Trial: 32621663
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.03% ointment twice daily for 2 weeks
Trial: 32574517
Drug: Antifibrotic drugs
RxNorm normalized name: Antihidrotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifibrotic drugs
Trial: 36184966
Drug: Park prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Park prescription (Park Rx) during routine clinical visits
Trial: 34922649
Drug: Namilumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Namilumab (150 mg, single intravenous dose)
Trial: 34922649
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg, single intravenous dose)
Trial: 32558214
Drug: Home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home treatment (HoT) after 4–8 weeks of inpatient treatment, with visits by a multi-professional team 3-4 times per week for the first two months and 1-2 times per week for the third and fourth months.
Trial: 34052365
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ibuprofen
Trial: 34664829
Drug: CT nano-contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT nano-contrast agent
Trial: 34664829
Drug: Traditional iohexol
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional iohexol contrast agent
Trial: 34936270
Drug: Oral sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sertraline hydrochloride dispersible tablets, 50 mg once a day
Trial: 35943472
Drug: Stenting plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stenting plus medical therapy (n=176)
Trial: 35943472
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone (n=182)
Trial: 35943472
Drug: Stenting plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stenting plus medical therapy (n=171)
Trial: 35943472
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone (n=178)
Trial: 35943472
Drug: Stenting plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stenting plus medical therapy (n=168)
Trial: 35943472
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone (n=170)
Trial: 35943472
Drug: Stenting plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stenting plus medical therapy (n=160)
Trial: 35943472
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone (n=159)
Trial: 35434041
Drug: L. plantarum
RxNorm normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. plantarum Lp3a; 2×1.0×10^10 CFU for 7 days
Trial: 35198149
Drug: 1000 IU
RxNorm normalized name: D 1000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU vitamin D daily
Trial: 33901574
Drug: Pharmacogenetic optimization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetic optimization arm (varenicline for fast metabolizers, nicotine patch for slow metabolizers)
Trial: 34296374
Drug: Pivotal response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pivotal response treatment (PRT), conducted three times a week for 2 months, totaling 24 one-hour sessions
Trial: 35500453
Drug: 3-day high-fat
RxNorm normalized name: olive oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day high-fat diet (500 mL of cream, 1700 kcal)
Trial: 34666728
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg every night at bedtime
Trial: 34666728
Drug: Pumpkin seed
RxNorm normalized name: PUMPKIN SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pumpkin seed oil 360 mg twice a day
Trial: 32763240
Drug: SER-287 after
RxNorm normalized name: SER-287
DrugBank: SER-287 (DB18204)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SER-287 after vancomycin preconditioning (daily dosing)
Trial: 32763240
Drug: SER-287 (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SER-287 (weekly dosing)
Trial: 32763240
Drug: SER-287 (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SER-287 (weekly dosing after vancomycin)
Trial: 32873473
Drug: Fluoroquinolone (usually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroquinolone (usually levofloxacin) monotherapy, 54% of treatments in both settings
Trial: 34850428
Drug: 0.1% pH‐balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% pH‐balanced chlorine dioxide spray
Trial: 34850428
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water spray (placebo control)
Trial: 34547400
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of lipopolysaccharide (LPS) at a dose of 0.6 ng/kg body weight
Trial: 33370165
Drug: Salacia chinensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salacia chinensis extract (150, 300, or 600 mg)
Trial: 33370165
Drug: Salacia chinensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salacia chinensis extract (600 mg/day)
Trial: 36484021
Drug: Loxoprofen Sodium
RxNorm normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Loxoprofen Sodium Cataplasm combined with extracorporeal shock wave therapy (ESWT) and transcutaneous electrical nerve stimulation (TENS)
Trial: 35215461
Drug: Nutrition and
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition and exercise intervention (bi‐weekly counselling for individualized energy and high dairy protein diet; walking goal of 10,000 steps/day)
Trial: 32758298
Drug: Intravenous melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous melatonin (IVM) 5 mg/kg/day for 7 days
Trial: 32758298
Drug: Placebo 5
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 5 mg/kg/day for 7 days
Trial: 34554015
Drug: Optimal allocation
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal allocation to treatments in a sequential multiple assignment randomized trial
Trial: 34091468
Drug: Steroid Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid Injection
Trial: 34940059
Drug: TSH concentration
RxNorm normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TSH concentration <0.1 µU/mL
Trial: 34940059
Drug: TSH concentration
RxNorm normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TSH concentration 0.4‐4.0 µU/mL
Trial: 34940059
Drug: TSH concentration
RxNorm normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TSH concentration 0.1‐0.39 µU/mL
Trial: 32728920
Drug: NAMI Provider
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAMI Provider Education Program - a 15-h contact-based adjunctive curriculum
Trial: 34036235
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus chemotherapy (Bev plus CTx)
Trial: 34036235
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (CTx) alone
Trial: 35077429
Drug: Perforating fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perforating fat injections (2.6 ± 1.6 ml of fat injected per foot at one to two sites)
Trial: 35077429
Drug: Perforating fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perforating fat injections
Trial: 33378139
Drug: Pretomanid 400
RxNorm normalized name: Pretomanid
DrugBank: Pretomanid (DB05154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pretomanid 400 mg
Trial: 33378139
Drug: Pretomanid 1000
RxNorm normalized name: Pretomanid
DrugBank: Pretomanid (DB05154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pretomanid 1000 mg
Trial: 33378139
Drug: Pretomanid 400
RxNorm normalized name: Pretomanid
DrugBank: Pretomanid (DB05154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pretomanid 400 mg plus Moxifloxacin 400 mg
Trial: 33025342
Drug: Ozanimod (0.23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod (0.23 mg on days 1-4, 0.46 mg on days 5-7, 0.92 mg on days 8-10, and 1.84 mg on days 11-30) + Pseudoephedrine (PSE) 60 mg on day 30
Trial: 33025342
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Pseudoephedrine (PSE) 60 mg on day 30
Trial: 34244284
Drug: Mechanical and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical and oral antibiotic bowel preparation (MOABP)
Trial: 34544182
Drug: Lactate-guided therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate-guided therapy
Trial: 35304275
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Cassia seed powder (0.3 g once daily)
Trial: 35304275
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Cassia seed powder (3.0 g once daily)
Trial: 37535775
Drug: Ozone injection
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone injection
Trial: 35367469
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust (DE) at 20 μg/m3
Trial: 35367469
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust (DE) at 50 μg/m3
Trial: 35367469
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust (DE) at 150 μg/m3
Trial: 36087008
Drug: Batoclimab 680
RxNorm normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batoclimab 680 mg with IVMP
Trial: 36087008
Drug: Batoclimab 340
RxNorm normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batoclimab 340 mg with IVMP
Trial: 35547000
Drug: Chiglitazar (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiglitazar (32 mg)
Trial: 35547000
Drug: Chiglitazar (48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiglitazar (48 mg)
Trial: 33710299
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of the oral GABA reuptake inhibitor tiagabine
Trial: 35981820
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapy with conservative management
Trial: 35981820
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapy with invasive management
Trial: 32541132
Drug: Hydrogen (H2)
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen (H2) therapy
Trial: 32541132
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no H2 therapy)
Trial: 32541132
Drug: H2 +
RxNorm normalized name: Histamine H2 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 + chemotherapy
Trial: 32541132
Drug: H2 +
RxNorm normalized name: Histamine H2 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 + targeted therapy
Trial: 32541132
Drug: H2 +
RxNorm normalized name: Histamine H2 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 + immunotherapy
Trial: 32541132
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy groups (H2 with chemotherapy, targeted therapy, or immunotherapy)
Trial: 35738852
Drug: Ranolazine treatment
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine treatment
Trial: 35738852
Drug: Ranolazine treatment
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine treatment in patients with cardiac resynchronization therapy (CRT) ICDs
Trial: 35738852
Drug: Ranolazine treatment
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine treatment in patients with ICDs without CRT
Trial: 35738852
Drug: Concomitant AAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant AAD therapy
Trial: 33177429
Drug: Various surgical
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various surgical treatments for tibial plateau fractures
Trial: 37638083
Drug: Morphine (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (control group)
Trial: 33451253
Drug: Eccentric loading
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eccentric loading program followed by stretching exercises combined with extracorporeal shockwave therapy (ESWT)
Trial: 32223566
Drug: Ayurvedic multiherbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic multiherbal medication administered daily for 1 month followed by 5 months of oral medication.
Trial: 33091863
Drug: Total liver
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total liver volume (T), left liver volume (L), right liver volume (R), caudate liver volume (C), spleen volume (S), L/T ratio, C/T ratio
Trial: 36129886
Drug: Jewelry-making sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jewelry-making sessions held twice a week for four weeks
Trial: 32835877
Drug: 5-Aminolevulinic Acid-mediated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Aminolevulinic Acid-mediated Photodynamic Therapy (5-ALA-PDT)
Trial: 33001138
Drug: Hydroxychloroquine, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine, 600 mg daily for 8 weeks
Trial: 33969792
Drug: Vancomycin-heparin-lock
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin-heparin-lock
Trial: 33969792
Drug: Non-heparin, high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-heparin, high-dose vancomycin-lock
Trial: 32729820
Drug: JY09 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JY09 6.0 mg
Trial: 32729820
Drug: JY09 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JY09 (various doses 0.3, 0.7, 1.5, 3.0, and 6.0 mg)
Trial: 34171938
Drug: AS201‐01 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS201‐01 tablets (4 tablets, twice daily for 4 days)
Trial: 34171938
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (4 tablets, twice daily for 4 days)
Trial: 32623839
Drug: metformin 1,000‐1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin 1,000‐1,500 mg daily
Trial: 35501887
Drug: Trained community‐oriented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trained community‐oriented resource persons (CORPs) conducting community‐based screening of BP, referral, diagnosis confirmation, initial treatment, monthly home‐based follow-up care, and health education.
Trial: 35501887
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (diagnosis, treatment and follow‐up care in hospital of a patient’s choice).
Trial: 33958325
Drug: Tight-control/treat-to-target strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight-control/treat-to-target strategy (TC/T2T) with visits every 4 weeks and treatment intensification until achieving ASDAS <2.1
Trial: 33958325
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (UC) with visits every 12 weeks and treatment at the rheumatologist's discretion
Trial: 34521465
Drug: MED intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MED intervention (medication review by a pharmacist and geriatrician in the ED)
Trial: 35137699
Drug: Antipsychotics (off-label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics (off-label use)
Trial: 35137699
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of antipsychotics after 4 months
Trial: 33567589
Drug: Water Replenishment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water Replenishment Group 1 (1000 mL)
Trial: 33567589
Drug: Water Replenishment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water Replenishment Group 2 (500 mL)
Trial: 33567589
Drug: Water Replenishment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water Replenishment Group 3 (200 mL)
Trial: 36076107
Drug: Inhaled vanilla
RxNorm normalized name: Vanilla
DrugBank: Vanilla (DB10576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled vanilla essential oil (VEO)
Trial: 35377106
Drug: Inhaled lavender
RxNorm normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled lavender essential oil (LEO)
Trial: 35938913
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase before endovascular treatment
Trial: 35938913
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment only
Trial: 32539893
Drug: CS200 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS200 (200 mg CS per kg feed)
Trial: 32539893
Drug: CS100 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS100 (100 mg CS per kg feed)
Trial: 35014145
Drug: Triple Therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple Therapy (metformin/exenatide/pioglitazone)
Trial: 35014145
Drug: Conventional Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Therapy (metformin → glipizide → glargine insulin)
Trial: 35014145
Drug: Triple Therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple Therapy
Trial: 32394855
Drug: Selexipag (doses:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selexipag (doses: 1200‐1600 µg b.i.d., 600‐1000 µg b.i.d., 200‐400 µg b.i.d.)
Trial: 35251561
Drug: EPOC training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPOC training in addition to conventional medication
Trial: 35251561
Drug: Conventional hypertension
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional hypertension medication